Wall Street brokerages predict that Blueprint Medicines Corporation (NASDAQ:BPMC) will post sales of $4.32 million for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Blueprint Medicines’ earnings, with estimates ranging from $1.13 million to $5.94 million. Blueprint Medicines reported sales of $7.69 million during the same quarter last year, which suggests a negative year over year growth rate of 43.8%. The company is expected to issue its next earnings report on Thursday, March 8th.

On average, analysts expect that Blueprint Medicines will report full-year sales of $4.32 million for the current financial year, with estimates ranging from $20.92 million to $25.74 million. For the next financial year, analysts forecast that the firm will post sales of $12.12 million per share, with estimates ranging from $4.50 million to $24.24 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that that provide coverage for Blueprint Medicines.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.96) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.90) by ($0.06). Blueprint Medicines had a negative net margin of 437.83% and a negative return on equity of 43.11%. The company had revenue of $8.07 million for the quarter, compared to the consensus estimate of $5.35 million. During the same period in the previous year, the business posted ($0.62) earnings per share. The firm’s revenue was up 31.0% compared to the same quarter last year.

A number of analysts have recently weighed in on BPMC shares. Cowen restated a “buy” rating on shares of Blueprint Medicines in a research note on Friday, November 10th. Morgan Stanley raised their target price on Blueprint Medicines from $45.00 to $78.00 and gave the company an “overweight” rating in a research note on Monday, October 23rd. ValuEngine lowered Blueprint Medicines from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Jefferies Group reiterated a “buy” rating and issued a $56.00 price objective on shares of Blueprint Medicines in a research report on Tuesday, September 5th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $80.00 price objective (up from $66.00) on shares of Blueprint Medicines in a research report on Wednesday, November 1st. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $83.78.

In other Blueprint Medicines news, insider Anthony L. Boral sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $70.40, for a total transaction of $352,000.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Daniel Lynch sold 2,500 shares of the firm’s stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $60.00, for a total value of $150,000.00. Following the transaction, the director now owns 209,342 shares in the company, valued at approximately $12,560,520. The disclosure for this sale can be found here. Over the last quarter, insiders sold 72,639 shares of company stock valued at $4,871,743. Corporate insiders own 3.40% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC boosted its stake in Blueprint Medicines by 10.8% during the second quarter. FMR LLC now owns 5,300,589 shares of the biotechnology company’s stock valued at $268,581,000 after buying an additional 516,835 shares during the period. BlackRock Inc. lifted its stake in shares of Blueprint Medicines by 39.6% in the 2nd quarter. BlackRock Inc. now owns 2,864,255 shares of the biotechnology company’s stock valued at $145,131,000 after acquiring an additional 811,820 shares during the last quarter. Lord Abbett & CO. LLC lifted its stake in shares of Blueprint Medicines by 0.5% in the 2nd quarter. Lord Abbett & CO. LLC now owns 1,729,169 shares of the biotechnology company’s stock valued at $87,617,000 after acquiring an additional 8,903 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Blueprint Medicines by 16.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,415,963 shares of the biotechnology company’s stock valued at $71,746,000 after acquiring an additional 195,517 shares during the last quarter. Finally, State Street Corp lifted its stake in shares of Blueprint Medicines by 76.8% in the 2nd quarter. State Street Corp now owns 1,400,035 shares of the biotechnology company’s stock valued at $70,936,000 after acquiring an additional 608,296 shares during the last quarter. Hedge funds and other institutional investors own 91.40% of the company’s stock.

Shares of Blueprint Medicines (NASDAQ BPMC) traded down $6.83 during trading hours on Thursday, hitting $75.33. The stock had a trading volume of 1,074,786 shares, compared to its average volume of 450,349. Blueprint Medicines has a 52 week low of $25.34 and a 52 week high of $92.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.28 and a quick ratio of 11.28.

ILLEGAL ACTIVITY NOTICE: “Blueprint Medicines Corporation (BPMC) Expected to Announce Quarterly Sales of $4.32 Million” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/12/14/blueprint-medicines-corporation-bpmc-expected-to-announce-quarterly-sales-of-4-32-million.html.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Get a free copy of the Zacks research report on Blueprint Medicines (BPMC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.